$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock $celz

$celz Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000147793223002123 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$18.60K	$88.60K
YoY Change	-100.0%	-72.55%	0.96%
Cost Of Revenue	$0.00	$5.700K	$28.49K
YoY Change	-100.0%	-85.55%	-40.58%
Gross Profit	$0.00	$12.90K	$60.11K
YoY Change	-100.0%	-54.42%	51.01%
Gross Profit Margin		69.35%	67.84%
Selling, General & Admin	$771.0K	$899.6K	$3.944M
YoY Change	-31.77%	-37.0%	33.03%
% of Gross Profit		6973.64%	6560.65%
Research & Development	$319.0K	$5.000M	$6.269M
YoY Change	3090.29%	9900.0%	5641.76%
% of Gross Profit		38759.69%	10429.14%
Depreciation & Amortization	$23.02K	$23.02K	$92.08K
YoY Change	0.0%	0.0%	0.0%
% of Gross Profit		178.45%	153.19%
Operating Expenses	$1.113M	$5.000M	$10.30M
YoY Change	-4.3%	233.1%	225.5%
Operating Profit	-$1.113M	-$4.987M	-$10.24M
YoY Change	-3.62%	238.63%	227.72%
Interest Expense	$50.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
% of Operating Profit
Other Income/Expense, Net	$61.15K	$62.25K	$100.3K
YoY Change			-99.55%
Pretax Income	-$1.052M	-$6.216M	-$10.14M
YoY Change	-8.91%	60.39%	-152.8%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.052M	-$6.216M	-$10.14M
YoY Change	-8.91%	60.39%	-152.8%
Net Earnings / Revenue		-33417.69%	-11449.26%
Basic Earnings Per Share			-$0.93
Diluted Earnings Per Share	-$0.07	-$0.44	-$0.93
COMMON SHARES
Basic Shares Outstanding	14.08M shares	14.08M shares	10.93M shares
Diluted Shares Outstanding			10.93M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.516M	$8.321M	$8.321M
YoY Change	4.04%	-22.41%	-22.41%
Cash & Equivalents	$9.516M	$8.321M
Short-Term Investments
Other Short-Term Assets	$5.287M	$10.42M	$10.42M
YoY Change	8039.16%
Inventory	$10.19K	$10.19K	$10.19K
Prepaid Expenses
Receivables		$0.00	$0.00
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$14.81M	$18.75M	$18.75M
YoY Change	60.56%	74.6%	74.6%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.280K	$3.280K	$3.280K
YoY Change	-0.03%	-0.03%	0.0%
Total Long-Term Assets	$415.9K	$438.9K	$438.9K
YoY Change	-18.13%	-17.34%	-17.34%
TOTAL ASSETS
Total Short-Term Assets	$14.81M	$18.75M	$18.75M
Total Long-Term Assets	$415.9K	$438.9K	$438.9K
Total Assets	$15.23M	$19.19M	$19.19M
YoY Change	56.46%	70.27%	70.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$353.4K	$3.268M	$3.268M
YoY Change	5.29%	328.89%	328.89%
Accrued Expenses	$39.92K	$39.92K	$39.92K
YoY Change	33.42%	63.71%	63.67%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$407.5K	$3.322M	$3.322M
YoY Change	7.3%	216.21%	216.22%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$407.5K	$3.322M	$3.322M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$407.5K	$3.322M	$3.322M
YoY Change	7.3%	216.22%	216.22%
SHAREHOLDERS EQUITY
Retained Earnings	-$54.86M	-$53.81M
YoY Change	22.4%	23.23%
Common Stock	$14.08K	$14.08K
YoY Change	115.87%	122.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$0.00
YoY Change
Treasury Stock Shares
Shareholders Equity	$14.82M	$15.86M	$15.86M
YoY Change
Total Liabilities & Shareholders Equity	$15.23M	$19.19M	$19.19M
YoY Change	56.46%	70.27%	70.27%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$1.052M	-$6.216M	-$10.14M
YoY Change	-8.91%	60.39%	-152.8%
Depreciation, Depletion And Amortization	$23.02K	$23.02K	$92.08K
YoY Change	0.0%	0.0%	0.0%
Cash From Operating Activities	-$3.842M	-$3.591M	-$7.797M
YoY Change	143.62%	209.24%	251.88%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$5.037M	-$5.057M	-$10.08M
YoY Change
Cash From Investing Activities	$5.037M	-$5.057M	-$10.08M
YoY Change		-2628.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$15.47M
YoY Change			4.83%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$0.00	0.000	$15.47M
YoY Change		-100.0%	20.48%
NET CHANGE
Cash From Operating Activities	-$3.842M	-3.591M	-$7.797M
Cash From Investing Activities	$5.037M	-5.057M	-$10.08M
Cash From Financing Activities	$0.00	0.000	$15.47M
Net Change In Cash	$1.196M	-8.649M	-$2.403M
YoY Change	-175.83%	-203.63%	-122.62%
FREE CASH FLOW
Cash From Operating Activities	-$3.842M	-$3.591M	-$7.797M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001187953
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2021Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7	shares
CY2021Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	31016	usd
CY2021	celz	Expiration Period Of Finite Lived Intangible Assets ExpirationPeriodOfFiniteLivedIntangibleAssets	2026
CY2021	celz	Expected Amount Of Amortization ExpectedAmountOfAmortization	9972	usd
CY2022	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	111817	shares
CY2022	celz	Class Of Warrant Term ClassOfWarrantTerm	P5Y
CY2021	celz	Valuation Allowance ValuationAllowance	1	pure
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-53500
CY2022	dei	Entity Registrant Name EntityRegistrantName	CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-0622284
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	211 E Osborn Road
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Phoenix
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	AZ
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	85012
CY2022	dei	City Area Code CityAreaCode	480
CY2022	dei	Local Phone Number LocalPhoneNumber	399-2822
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022	dei	Trading Symbol TradingSymbol	CELZ
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	6193548	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	14076238	shares
CY2022	dei	Auditor Name AuditorName	Haynie & Company
CY2022	dei	Auditor Location AuditorLocation	Salt Lake City, Utah
CY2022	dei	Auditor Firm AuditorFirmId	457
CY2022Q4	us-gaap	Cash Cash	8320519	usd
CY2021Q4	us-gaap	Cash Cash	10723870	usd
CY2022Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	10078617	usd
CY2021Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	0	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2485	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	10194	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	10866	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	338120	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	0	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	18747450	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	10737221	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	3281	usd
CY2021Q4	us-gaap	Other Assets OtherAssets	3281	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	435595	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	527679	usd
CY2022Q4	us-gaap	Assets Assets	19186326	usd
CY2021Q4	us-gaap	Assets Assets	11268181	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3267538	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	761862	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	39920	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24385	usd
CY2022Q4	us-gaap	Management Fee Payable ManagementFeePayable	0	usd
CY2021Q4	us-gaap	Management Fee Payable ManagementFeePayable	250000	usd
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	14194	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	14194	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3321652	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1050441	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3321652	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1050441	usd
CY2022Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14076246	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6338872	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14076238	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6338864	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	14077	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	6339	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	69662455	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	53879215	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-53811858	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-43667814	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	15864674	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	10217740	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19186326	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11268181	usd
CY2022	us-gaap	Revenues Revenues	88600	usd
CY2021	us-gaap	Revenues Revenues	87754	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	28491	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	47949	usd
CY2022	us-gaap	Gross Profit GrossProfit	60109	usd
CY2021	us-gaap	Gross Profit GrossProfit	39805	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6268854	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	109180	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3943543	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2964490	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	92084	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	92084	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	10304481	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	3165754	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-10244372	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-3125949	usd
CY2022	us-gaap	Interest Expense InterestExpense	0	usd
CY2021	us-gaap	Interest Expense InterestExpense	4278433	usd
CY2022	celz	Gain On Extinguishment Of Convertible Notes GainOnExtinguishmentOfConvertibleNotes	0	usd
CY2021	celz	Gain On Extinguishment Of Convertible Notes GainOnExtinguishmentOfConvertibleNotes	585601	usd
CY2022	celz	Change In Fair Value Of Derivatives Liabilities ChangeInFairValueOfDerivativesLiabilities	0	usd
CY2021	celz	Change In Fair Value Of Derivatives Liabilities ChangeInFairValueOfDerivativesLiabilities	26030549	usd
CY2022	us-gaap	Other Income OtherIncome	100328	usd
CY2021	us-gaap	Other Income OtherIncome	0	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	100328	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	22337717	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10144044	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	19211768	usd
CY2022	us-gaap	Provision For Other Losses ProvisionForOtherLosses	0	usd
CY2021	us-gaap	Provision For Other Losses ProvisionForOtherLosses	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10144044	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	19211768	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.93
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	7.37
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.93
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.61
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10932035	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2605057	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10932035	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3248619	shares
CY2022	us-gaap	Profit Loss ProfitLoss	-10144044	usd
CY2021	us-gaap	Profit Loss ProfitLoss	19211768	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	68746	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	595380	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	92084	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	92084	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	4157850	usd
CY2022	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	usd
CY2021	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	26030549	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10723870	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022	celz	Increase In Principal And Accrued Interest Balances Due To Penalty Provision IncreaseInPrincipalAndAccruedInterestBalancesDueToPenaltyProvision	0	usd
CY2021	celz	Increase In Principal And Accrued Interest Balances Due To Penalty Provision IncreaseInPrincipalAndAccruedInterestBalancesDueToPenaltyProvision	93821	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	585601	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2485	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2485	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-672	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	10866	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	338120	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	0	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2505676	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	410963	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	15535	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	20635	usd
CY2022	celz	Increase Decrease In Management Fee Payable IncreaseDecreaseInManagementFeePayable	0	usd
CY2021	celz	Increase Decrease In Management Fee Payable IncreaseDecreaseInManagementFeePayable	-168782	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7796966	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2215782	usd
CY2022	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit	10078617	usd
CY2021	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10078617	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	15471775	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14758488	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	457	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	3887750	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	5251176	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	443239	usd
CY2022	celz	Payment Of Deferred Offering Costs PaymentOfDeferredOfferingCosts	0	usd
CY2021	celz	Payment Of Deferred Offering Costs PaymentOfDeferredOfferingCosts	-3281	usd
CY2022	celz	Payment Of Offering Costs PaymentOfOfferingCosts	0	usd
CY2021	celz	Payment Of Offering Costs PaymentOfOfferingCosts	-105180	usd
CY2021	celz	Preferred Stock Redemption PreferredStockRedemption	196751	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	435040	usd
CY2022	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	462000	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	usd
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	223394	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	220000	usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
CY2021	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	705405	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15472232	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12841640	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2403351	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	10625858	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10723870	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	98012	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8320519	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	9186	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	celz	Accrued Dividends On Preferred Stock AccruedDividendsOnPreferredStock	0	usd
CY2021	celz	Accrued Dividends On Preferred Stock AccruedDividendsOnPreferredStock	27725	usd
CY2022	celz	Warrants Issued With Notes Payable As A Service Fee WarrantsIssuedWithNotesPayableAsAServiceFee	0	usd
CY2021	celz	Warrants Issued With Notes Payable As A Service Fee WarrantsIssuedWithNotesPayableAsAServiceFee	2097629	usd
CY2022	celz	Conversion Of Notes Payable Accrued Interest And Derivative Liabilities Into Common Stock ConversionOfNotesPayableAccruedInterestAndDerivativeLiabilitiesIntoCommonStock	0	usd
CY2021	celz	Conversion Of Notes Payable Accrued Interest And Derivative Liabilities Into Common Stock ConversionOfNotesPayableAccruedInterestAndDerivativeLiabilitiesIntoCommonStock	13747415	usd
CY2022	celz	Conversion Of Management Fees And Patent Liability Into Common Stock ConversionOfManagementFeesAndPatentLiabilityIntoCommonStock	250000	usd
CY2021	celz	Conversion Of Management Fees And Patent Liability Into Common Stock ConversionOfManagementFeesAndPatentLiabilityIntoCommonStock	50000	usd
CY2022	celz	Discounts On Convertible Notes Payable Due To Derivative Liabilities DiscountsOnConvertibleNotesPayableDueToDerivativeLiabilities	0	usd
CY2021	celz	Discounts On Convertible Notes Payable Due To Derivative Liabilities DiscountsOnConvertibleNotesPayableDueToDerivativeLiabilities	134640	usd
CY2022	celz	Exchange Of Preferred Stock For Notes Payable ExchangeOfPreferredStockForNotesPayable	0	usd
CY2021	celz	Exchange Of Preferred Stock For Notes Payable ExchangeOfPreferredStockForNotesPayable	572275	usd
CY2022	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	0	usd
CY2021	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	989346	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-39803010	usd
CY2021	celz	Proceeds From Sales Of Preferred Stock Amount ProceedsFromSalesOfPreferredStockAmount	462000	usd
CY2021	celz	Common Stock Issued For Related Party Management And Patent Liabilities Amount CommonStockIssuedForRelatedPartyManagementAndPatentLiabilitiesAmount	50000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14758488	usd
CY2021	celz	Offering Costs OfferingCosts	-105180	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1383332	usd
CY2021	celz	Relief Of Derivative Liabilities ReliefOfDerivativeLiabilities	12364084	usd
CY2021	celz	Dividends On Preferred Stock DividendsOnPreferredStock	-27725	usd
CY2021	celz	Cashless Exercise Of Warrants Amount CashlessExerciseOfWarrantsAmount	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2097629	usd
CY2021	celz	Preferred Stock Redemptions Amounts PreferredStockRedemptionsAmounts	-769026	usd
CY2021	celz	Stock Based Compensation StockBasedCompensation	595380	usd
CY2021	celz	Differences In Shares From Reverse Stock Split Amount DifferencesInSharesFromReverseStockSplitAmount	0	usd
CY2021	celz	Revaluation Of Warrants Related To Ratchet Provision Adjustment RevaluationOfWarrantsRelatedToRatchetProvisionAdjustment	0	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	19211768	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	10217740	usd
CY2022	celz	Issuance Of Common Stock And Accompanying Warrants Net Of Issuance Costs Amount IssuanceOfCommonStockAndAccompanyingWarrantsNetOfIssuanceCostsAmount	15471775	usd
CY2022	celz	Common Stock Issued For Related Party Management And Patent Liabilities Amount CommonStockIssuedForRelatedPartyManagementAndPatentLiabilitiesAmount	250000	usd
CY2022	celz	Common Stock Issued For Warrant Exercise Amount CommonStockIssuedForWarrantExerciseAmount	457	usd
CY2022	celz	Stock Based Compensation StockBasedCompensation	68746	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10144044	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	15864674	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><em>Use of Estimates – </em></strong>The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2021Q3	srt	Mortgage Loans On Real Estate Principal Amount Of Delinquent Loans MortgageLoansOnRealEstatePrincipalAmountOfDelinquentLoans	4456176	usd
CY2022Q4	us-gaap	Time Deposits At Or Above Fdic Insurance Limit TimeDepositsAtOrAboveFDICInsuranceLimit	250000	usd
CY2020Q4	celz	License Agreement Description LicenseAgreementDescription	(the “Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement
CY2021Q3	celz	Company Paid CompanyPaid	40000	usd
CY2021Q3	celz	Obligation Of The Initial Payment ObligationOfTheInitialPayment	300000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	40000	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	30000	usd
CY2021Q3	celz	Common Stock Issue CommonStockIssue	84656	usd
CY2021Q1	celz	Company Paid CompanyPaid	50000	usd
CY2021Q1	celz	Obligation Of The Initial Payment ObligationOfTheInitialPayment	300000	usd
CY2021Q1	celz	Common Stock Issue CommonStockIssue	89286	usd
CY2021Q4	celz	Obligation Of The Initial Payment ObligationOfTheInitialPayment	300000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6268854	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	109180	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7	shares
CY2016Q1	celz	No Of Share Exchange NoOfShareExchange	431111	shares
CY2016Q1	celz	Restricted Common Stock RestrictedCommonStock	100000	usd
CY2022Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	31016	usd
CY2022	celz	Expected Amount Of Amortization ExpectedAmountOfAmortization	9972	usd
CY2017Q2	celz	Payments Upon Completion Of Irb Clinical Trial PaymentsUponCompletionOfIrbClinicalTrial	200000	usd
CY2017Q2	celz	Payments In The Event Of Commercialization Of Technology PaymentsInTheEventOfCommercializationOfTechnology	300000	usd
CY2020Q4	celz	Common Stock Issue CommonStockIssue	6667	usd
CY2022Q4	celz	Company Paid CompanyPaid	50000	usd
CY2022Q4	celz	Obligation Of The Initial Payment ObligationOfTheInitialPayment	300000	usd
CY2022Q4	celz	Common Stock Issue CommonStockIssue	133	usd
CY2022	celz	Continuing Royalty Description ContinuingRoyaltyDescription	Within thirty (30) days of the end of each calendar quarter during the term of this Agreement, Licensee will pay Licensor five percent (5%) of the Net Income of ImmCelz™. during such calendar quarter (the “Continuing Royalty”)
CY2020Q4	celz	License Fees LicenseFees	250000	usd
CY2021Q1	celz	Number Of Share Issuance Of Common Stock To Jadi Cell NumberOfShareIssuanceOfCommonStockToJadiCell	180180	shares
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	92085	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Two FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo	92085	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Three FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree	91774	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Four FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour	54650	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	30000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	75002	usd
CY2022Q4	celz	Total Future Amortization Cost TotalFutureAmortizationCost	435595	usd
CY2021Q4	celz	Licensing Agreements Beginning Balance LicensingAgreementsBeginningBalance	760000	usd
CY2021Q4	celz	Accumulated Amortization Beginning Balance AccumulatedAmortizationBeginningBalance	-232321	usd
CY2022	celz	Accumulated Amortization Addition Of New Assets AccumulatedAmortizationAdditionOfNewAssets	0	usd
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0	usd
CY2022	celz	Accumulated Amortization AccumulatedAmortization	-92084	usd
CY2022Q4	celz	Licensing Agreementsendingbalance LicensingAgreementsendingbalance	760000	usd
CY2022Q4	celz	Accumulated Amortization Ending Balance AccumulatedAmortizationEndingBalance	-324405	usd
CY2021Q3	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.05	pure
CY2021Q3	celz	Original Sale Discount Percentage OriginalSaleDiscountPercentage	0.15	pure
CY2021Q3	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	4456176	usd
CY2021	celz	Amortization To Interest Expense AmortizationToInterestExpense	3299000	usd
CY2021	celz	Debt Conversion Shares Issued DebtConversionSharesIssued	789727	shares
CY2021	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	1383332	usd
CY2021	celz	Debt Conversion Converrted Instrument Shares Issued DebtConversionConverrtedInstrumentSharesIssued	37870	shares
CY2021	celz	Common Stock Issued For Cashless Warrant Exercise Shares CommonStockIssuedForCashlessWarrantExerciseShares	43167	shares
CY2021Q4	celz	Initial Derivative Liabilities InitialDerivativeLiabilities	1077757	usd
CY2021	celz	Fair Value Assumption Expected Terms FairValueAssumptionExpectedTerms	P1Y
CY2021Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	697602	usd
CY2021Q1	celz	Gain Loss Related To Change In Fair Market Value Of Derivative Liabilities GainLossRelatedToChangeInFairMarketValueOfDerivativeLiabilities	28476039	usd
CY2021Q3	us-gaap	Workers Compensation Discount Percent WorkersCompensationDiscountPercent	0.15	pure
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	usd
CY2022Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2991669	shares
CY2022Q2	celz	Purchase Of Pre Funded Warrant And Related Common Warrant PurchaseOfPreFundedWarrantAndRelatedCommonWarrant	15111112	shares
CY2022Q2	celz	Combined Offering Price Of Pre Funded Warrant And Related Common Warrant CombinedOfferingPriceOfPreFundedWarrantAndRelatedCommonWarrant	2.25
CY2022Q2	celz	Description Of Amendment DescriptionOfAmendment	pursuant to a Securities Purchase Agreement between the Company and the Purchasers dated as of April 28, 2022 (the “Purchase Agreement”), resulting in gross proceeds to the Company of approximately $17,000,000. The transaction was effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder
CY2022	celz	Common Warrants Exercise Price CommonWarrantsExercisePrice	2.00
CY2022	celz	Pre Funded Warrants Exercise Price PreFundedWarrantsExercisePrice	0.0001
CY2022Q2	celz	Purchase Of Warrants Shares PurchaseOfWarrantsShares	4563887	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2022	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0081	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.9295	pure
CY2022Q4	us-gaap	Share Price SharePrice	1.83
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.057	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.005	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.000	pure
CY2022Q4	celz	Initial Payment Amount InitialPaymentAmount	2000000	usd
CY2022Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5000000	usd
CY2022	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	2096475	usd
CY2021	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	325596	usd
CY2022	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	582461	usd
CY2021	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	90460	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2678936	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	416056	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4843337	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2097315	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	67086	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4843337	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2164401	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022	celz	Valuation Allowance ValuationAllowance	1	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.000	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.003	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.227	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.264	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.022	pure
CY2022	us-gaap	Provision For Other Losses ProvisionForOtherLosses	0	usd
CY2021	us-gaap	Provision For Other Losses ProvisionForOtherLosses	0	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	18000000.0	usd
CY2022	celz	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rates EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates	0.21	pure
CY2021	celz	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rates EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates	0.089	pure

Files In Submission

Name	View Source	Status
0001477932-23-002123-index-headers.html	Edgar Link	pending
0001477932-23-002123-index.html	Edgar Link	pending
0001477932-23-002123.txt	Edgar Link	pending
0001477932-23-002123-xbrl.zip	Edgar Link	pending
celz-20221231.xsd	Edgar Link	pending
celz_10k.htm	Edgar Link	pending
celz_10kimg1.jpg	Edgar Link	pending
celz_10kimg2.jpg	Edgar Link	pending
celz_10kimg3.jpg	Edgar Link	pending
celz_ex109.htm	Edgar Link	pending
celz_ex109img1.jpg	Edgar Link	pending
celz_ex109img10.jpg	Edgar Link	pending
celz_ex109img11.jpg	Edgar Link	pending
celz_ex109img12.jpg	Edgar Link	pending
celz_ex109img2.jpg	Edgar Link	pending
celz_ex109img3.jpg	Edgar Link	pending
celz_ex109img4.jpg	Edgar Link	pending
celz_ex109img5.jpg	Edgar Link	pending
celz_ex109img6.jpg	Edgar Link	pending
celz_ex109img7.jpg	Edgar Link	pending
celz_ex109img8.jpg	Edgar Link	pending
celz_ex109img9.jpg	Edgar Link	pending
celz_ex311.htm	Edgar Link	pending
celz_ex312.htm	Edgar Link	pending
celz_ex321.htm	Edgar Link	pending
celz_ex322.htm	Edgar Link	pending
celz_ex45.htm	Edgar Link	pending
celz-20221231_def.xml	Edgar Link	unprocessable
celz-20221231_lab.xml	Edgar Link	unprocessable
celz-20221231_cal.xml	Edgar Link	unprocessable
celz-20221231_pre.xml	Edgar Link	unprocessable
celz_10k_htm.xml	Edgar Link	completed
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock $celz

2023 Q1 Form 10-K Financial Statement

#000147793223002123 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock $celz

2023 Q1 Form 10-K Financial Statement

#000147793223002123 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock $celz